Head-To-Head Contrast: Fulcrum Therapeutics (FULC) and Its Rivals

Fulcrum Therapeutics (NASDAQ:FULC) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Fulcrum Therapeutics to related companies based on the strength of its analyst recommendations, profitability, valuation, risk, dividends, institutional ownership and earnings.

Risk & Volatility

Fulcrum Therapeutics has a beta of 2.82, indicating that its stock price is 182% more volatile than the S&P 500. Comparatively, Fulcrum Therapeutics’ competitors have a beta of 1.14, indicating that their average stock price is 14% more volatile than the S&P 500.

Profitability

This table compares Fulcrum Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-25.38%	-24.15%
Fulcrum Therapeutics Competitors	-12,359.35%	-203.09%	-30.93%

Earnings and Valuation

This table compares Fulcrum Therapeutics and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Fulcrum Therapeutics	$80.00 million	-$74.88 million	-3.05
Fulcrum Therapeutics Competitors	$698.13 million	$10.43 million	-15.34

Fulcrum Therapeutics’ competitors have higher revenue and earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 7.3% of Fulcrum Therapeutics shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for Fulcrum Therapeutics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4	7	1	0	1.75
Fulcrum Therapeutics Competitors	9847	15133	45517	1589	2.54

Fulcrum Therapeutics currently has a consensus price target of $8.20, indicating a potential upside of 121.92%. As a group, “Biotechnology” companies have a potential upside of 100.07%. Given Fulcrum Therapeutics’ higher possible upside, analysts plainly believe Fulcrum Therapeutics is more favorable than its competitors.

Summary

Fulcrum Therapeutics beats its competitors on 7 of the 13 factors compared.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.